1     
ABUSE DETERRENT OPIOID ANALGESIC DRUG PRODUCTS

2     
2015 GENERAL SESSION

3     
STATE OF UTAH

4     
Chief Sponsor: Jerry W. Stevenson

5     
House Sponsor: Michael S. Kennedy

6     

7     LONG TITLE
8     General Description:
9          This bill enacts language related to the study of abuse-deterrent opioid analgesic drug
10     products.
11     Highlighted Provisions:
12          This bill:
13          ▸     defines terms;
14          ▸     requires the Public Employees' Benefit and Insurance Program to:     
15               •     study the barriers to and efficacy of use of abuse-deterrent opioid analgesic drug
16     products; and
17               •     report to the Business and Labor Interim Committee and the Health and Human
18     Services Interim Committee; and
19          ▸     provides a repeal date.
20     Money Appropriated in this Bill:
21          None
22     Other Special Clauses:
23          None
24     Utah Code Sections Affected:
25     ENACTS:
26          49-20-412, Utah Code Annotated 1953
27          63I-2-249, Utah Code Annotated 1953
28     

29     Be it enacted by the Legislature of the state of Utah:

30          Section 1. Section 49-20-412 is enacted to read:
31          49-20-412. Study of abuse-deterrent opioid analgesic drug products.
32          (1) As used in this section:
33          (a) "Abuse-deterrent opioid analgesic drug product" means an opioid analgesic drug
34     product with labeling approved by the Food and Drug Administration indicating that the
35     product has properties that are expected to reduce abuse of the product.
36          (b) "Opioid analgesic drug product" means a product in the opioid analgesic drug class
37     that is prescribed to treat moderate to severe pain, regardless of whether the drug is combined
38     with other substances in a single product or dosage form.
39          (2) For purposes of the report required by Subsection (3), the program shall study
40     available information regarding the barriers to and the efficacy of the use of abuse-deterrent
41     opioid analgesic drug products.
42          (3) The program shall report to the Business and Labor Interim Committee and the
43     Health and Human Services Interim Committee by no later than the respective committee's
44     November 2015 interim committee meeting regarding the study required by Subsection (2).
45          Section 2. Section 63I-2-249 is enacted to read:
46          63I-2-249. Repeal dates -- Title 49.
47          Section 49-20-412 is repealed January 1, 2016.